Member Info for EGTP

To summarise the resource here is simply enormous and it has been simply enormous for a long time, the only reason the SP has been so low for so long is the unlikeliness they would ever get this resource out via major funding a takeover or a JV

But with shell striking next door and total drilling at the other side the facts and reality has significantly changed and won’t now be changing until we are told otherwise

Its simple this stock doesn’t need ramping just DYOR

Well had to top up as the Sp simply getting completely and utterly ridiculous here - they will be mass producing the new revised gold standard AffiDX test shortly

The company is already profitable (up 120% profit from year previous) tangible assets here are worth at least 28p Alone ?

Plus £8 mil to come from government which they will be paying - though May need to just get it directly from ODX !

GLA - DYOR

Part 2

Mass testing for all purposes including sewage monitoring (Deepverge using Affimers) is the direction the brave new world is heading, and nothing will stop this revolution happening. Not only will the best most accurate LFT’s save time, lives and infections spreading, they will also be able to cut down truancy and instantly endorse sick pay and right to time off work - this is what Medusa-19 have their focus on, and this is why they’ve been so patient for so long.

I was first attracted to this stock in April 2020 simply because of it’s AffiDX solution, but having read about Affimers and understood their simply brilliant performance and adaptability to bind to just about every known disease and virus particle within the body – I now understand the bigger picture

If your in just for the AffiDX fine - the world will need the best LFT tests to detect Covid for the next 5 to 10 years. Yes early boats have been missed, but 1000’s more await (just like Google finally championed over Altavista and Ask Jeeves) but do understand it’s just a sideline, which I believe will become one of many multi £billion diagnostic arms of Avacta, along with the precision platform deals, Affimer Sales, Partnerships and it’s own products namely AVA6000 / 3996.

Avacta’s deal with LG Chem is worth more than double the current Market cap alone, the milestones recently achieved with Point Bio Pharma seem to be totally ignored, and the fact Avacta's market cap has dropped by £100 million since the Affidx update somehow suggests the market now believes £100 million of LFT sales profit has been lost.

As far as the Uk Govs attitude to Avacta is concerned - well the political landscape will be changing shortly too. I was reliably informed 2 weeks ago that the Government were tripling the supply of free lateral flow tests in January and February to 300 million per month. They also intended to distribute 600,000 packs of 7 tests on gov.uk directly to homes every day, this is an overview of the UK market alone.

For me Avacta is an investment, not a day trade or short hold, so don’t buy £1 of this stock until you properly understand Avacta and it’s Affimers

GLA and DYOR

Part 1

Just to cover some of my previous - yes regrettably for most holders, I still 100% agree with the decision to temporarily pause AffiDX, in order to revise and quickly relaunch an improved version. This just had to be done, and the greater good will be soon be clear, when AVA6000 feedback is released, and the trials in the US commence.

To venture a little further into AVA6000, try not to blind yourselves, and others by the science. It’s simple, Avacta have found a way for its Affimers to deliver precision chemotherapy using standard doxorubicin delivery at up to 10 times normal strength, with virtually zero side effects. This is an absolutely stunning development, and means serious, and terminally ill cancer sufferers now have the option of gambling virtually nothing, for the chance of a normal healthy life.

And the best part - this isn’t a new novel treatment that needs years and years of trials, it’s just a modification of how the current treatments are being delivered, proof of concept is already in action ! and the UK trial results are imminent, if this news is as good as what one would expect the FDA to require to allow Avacta into the US - how much is this single delivery method for just one treatment alone worth to the world ?

Yes it’s true the market can’t see the wood for the trees, so I have to agree (in part) with some of the regular doomsday mob because they do have a point. And because the current market value is now so low, outsiders simply don’t believe its possible our company could have such good Technology. Its pure Psychology, if we were a £2 Billion market cap investors would invest seriously, so as a result the market may choose to even ignore the success of AVA6000 trials for now, simply because it doesn’t understand Avacta. And because it’s so obsessed with the SARS Cov Antigen test it can’t even comprehend the purpose and Benefit of Medusa-19 - which takes me back to another previous post

‘Who are Medusa-19 and what use are they to Avacta’

Because of coronavirus, the world is now changing forever, which makes me pretty sure Hughes and Karmani couldn’t give a toss that their current avacta holding is only worth around ¼ of what it was around 6 months ago. Hughes and Kamani are totally focused on exploiting AffiDX via Medusa-19 to fit it into the new emerging world, and they know by doing so, they will open more doors for Avacta

As previous we know a home use LFT is now accepted to be as good as an x-ray, and in the very near future LFT’s with electronic signatures will be accepted instead of doctors notes for example common flu and exhaustion as well as Covid-19.

They will also be able to prove a claimant is not actually ill at all, or the illness is self inflicted example alcoholism and drug use.

No problems oddmoney - but Please don’t increase your investment Because if my commentary !

I’m just the average nobody that believes he can see into the future

Have good weekend all !

DYOR

Further to my last, I would also like to invite the de-rampers and doomsters, plus beg forgiveness in advance (to some genuine holders) to open their eyes and expand their minds even further to understand what has happened, and where things are now guaranteed to now go in the future

Back in 2001 A guy called Richard Colvin Reid inadvertently created a multi billion dollar Industry trying to blow up a plane. As a result you now cannot fly anywhere in the modern world without you, and your baggage’s been X-ray scanned.

Fast forward to 2022 it has now been accepted that home self testing / diagnosis is more accurate than going to see your GP, and it is at least as reliably accurate as going to hospital for a PCR test - which is in effect an x-ray scan.

The reason the avacta sars cov antigen test has been branded ‘AffiDX’ is because more tests are currently being developed using the cutting edge affimer technology https://en.wikipedia.org/wiki/Affimer to produce Cortisol, Sepsis, Vitamin D, Cholesterol ect (maybe even a test to detect delusion and stupidity for some ;-0)

As a result of Coronavirus Home Self testing / diagnosis will become a multi £trillion (never mind billion) industry within the next 5 to 10 years, anyone that doubts this needs to ask themselves this question.

How much money, time and valuable lives could be saved if Doctors, GP’s, Nurses and Hospital resources could do just what they used to do 50 years ago – rather than spending 90% of their current time confirming the obvious, as well as endless paperwork and phone calls – when this could have already be done and confirmed by the patient ?

I haven’t spoke with Kamani or Hughes personally, but can absolutely guarrantee they’ve no interest in just recovering to breakeven their £22 plus million investment in https://www.medusa19.com/ from the production / sale to the home user of maybe 50 million Affidx or ‘Meduflow’ tests as a result of their partnership / profit share with Avacta.

No sir - their vision is way beyond that, and from being major share holders in Avacta they have good reason to believe this, knowing full well how good Affimers and the precision technology they create are, to perfect these future home self tests in the pipeline

Mark my words the future of the world, and self diagnosis for Covid-19 is considerably bigger than the Affidx Antigen test produced by Avacta, which is in itself only a sideline (maybe 5%) of what Avacta Life Sciences is all about.

Hopefully the penny has now dropped for some !

GLA and DYOR

So if theres been no LFT income gained from the joint production efforts of mologic, Medusa19 (plus trial batches from Abingdon) so far, and there is to be no appreciable quantity of income likely to be gained by avacta in the near future when the quickly tweaked gold standard test is re-released

Why is the world not going to have use for such a product, when even the European governments predict coronavirus will be around causing further disruption for the next 5 to 6 years ?

And why oh why is one of the uk’s most powerful capable retailers, still sat patiently waiting to market the Meduflow test for home use to the EU, US and rest of the world in partnership with avacta, having already invested £22 million of their own cash to buy LFT manufacturing machines to produce this test independently ?

And If Medusa now expect the revised test to be a non runner why not produce and sell someone else’s test under licence ? it’s been widely commented there’s plenty of other tests around, and to state the obvious Medusa are only Interested in making money, so why stay loyal to a failed product ?

Lots of questions with obvious answers to me, so really difficult to understand the outright dumb naive stupidity of some on this board - presuming they are not Derampers with an agenda

DYOR

Again I empathise with all genuine holders here, I feel the short term pain too, but AS just had to do this to safeguard the companies credibility (beyond AIM traders).

We are on the verge of doing the impossible for a small cap, getting a Cancer cure product (AVA6000) into a real time US trial, this is unprecedented and would have needed 5 star trial data to achieve this (to be revealed shortly)

So with this in mind Avacta couldn't possibly risk their sideline LFT being pulled independently, as this could have effected the AVA6000 trial / AVA3996 selection, and confidence (beyond AIM) example the other major Pharma Avacta have partnerships with, major holders, maybe even Medusa-19, who are still holding out with a £22 plus mil investment to sell the AffiDX

This just had to be done and was clearly a tactical move also. It should also be noted Avacta with ABDX assistance must be very confident they can modify the current withdrawn LFT to produce an even better LFT than previous, and with reference to previous updates, this process should really not take long, if the AffiDX is as claimed quickly adaptable and flexible.

So I believe with all things considered, including the probability work on modifying the current LFT actually started before Christmas, we will hear good news about the new modified Gold Standard LFT very shortly, further endorsing the Affimer tech

DYOR

Like most others I don’t like the SP drop but totally support the reasoning behind this action - it was absolutely essential for Avactas future

And I’m pretty sure also very clever and tactical, don’t be surprised if the new test, which I suspected was already in development (after December omicron confirmed) is announced as ready in the next few days

All IMO of course, so I’ve duly topped up, do not under any circumstances do the same unless you believe as I do

After the darkest night - there’s always a brighter day !

GLA - DYOR

Yes the penny has finally dropped !

It is inevitable the Uk gov will want to buy the avacta AffiDX test made by Abdx in as large volumes as possible from some point in the very near future

Whether either company will actually wish to feel the need to even entertain such a proposal will be totally down to the Uk govs attitude, and not any specific need from either Abdx or Avacta

DYOR

Intraday today ;-)

Lol well I’m definitely not his ex wife oxygen !

Unfortunately John redwood is a fruit cake and completely irrelevant - best keep the pressure on your local MPs and media - example Huff post were first to break this early 2021 if anyone has any leverage into huff post that be ideal

Can still order AffiDX from bioserve right now in batches 10 x so no apparent problems with stock at https://bioservuk.com/basket/

We know mologic were the first to start manufacturing for bioserve, and I expect it to be confirmed shortly that another company have also been manufacturing/ supplying them too for quite some time

GLA and best wishes 2022

Always appreciate the hard work and research from the likes Energyshares, Bella, Marik, Poirot, Ophidian, Sportstrader, plus do enjoy the banter of Timster (and Mr Ripley, PL75 when palatable) and the new found uplifting optimism from Mr iceman888 (don’t spend all day on here so apologies if I’ve missed a few)

Its fair to say we are not where we hoped to be this time last year, but an incredible amount of progress has still been made and the pathway to the way the next 2 to 5 years is now so much clearer putting Avacta in a position multiples times stronger than 12 months ago.

It looks like we are about to crack the enigma code and hit the jackpot in Q1 2022, so try not to worry too much about the shorters, derampers they know absolutely nothing more than we do, and most likely much less.

Becoming successful in any walk of life is all about understanding where things are going and having a great idea to fit into that direction, plus good preparation and a solid foundation

I’m certain Avacta tick all these boxes

DYOR

It’s a bluff just fun and games - Jupiter added the extra to suppress the rise on 22nd December, hoping to force sp back down to low £1 region to finally buy their way out

I do also recall the main 4 green boxes didn’t even post a dicky bird until later that afternoon - coincidence or what ?

DYOR

Exactly Energyshares - your posts are always well researched well informed and very welcome

With all things considered avacta is without doubt the investment opportunity of a lifetime

DYOR

May have already been covered so apologies if so but if you now go to https://www.medusa19.com/

You will see the previous M-19 protein antibody test has now disappeared, all coverage now committed to Meduflow - conclusive prove as I’ve been saying all along that M-19’s sole existence and £22 million investment in LFT manufacturing equipment to produce up to 25 million tests per month was always for Avacta products only

DYOR

Yes so perfectly summarised

Welcome on board Mr Querusrobor and do please keep posting !

Why do I get the feeling TT will be confirmed tomorrow morning - with order details ?

Anyone else ?